Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Samsung+SK Hynix 42% of Kospi; TSMC >40% of Taiex. Goldman’s Moe: supply shock could force correction. Allocators risk doubling AI exposure.
The FLKR rally leans heavily on Samsung (roughly 25% of assets) and memory chip momentum. A guidance miss or North Korea shock could reverse gains.
The SBIR award validates GSI’s G-II chip for counter-drone use; Phase I contracts rarely translate to near-term revenue. The stock’s move may be premature.
First-quarter revenue beat expectations on $49 billion in assets. Cost reductions won't show until the second half, creating a margin lag that the next quarterly report will test.
FG-3246 Phase II interim data due Q4 2026; roxadustat Phase III results in 2H 2026. Cash extended to 2028 removes dilution overhang, setting up a two-catalyst year.
Founder Jonah Peretti exits as CEO. The cash infusion addresses near-term liquidity, while the implied valuation signals deep distress. Next catalyst: closing timeline and Allen's first strategic remarks.
Anthropic's Mythos has crushed most cybersecurity stocks in 2026, but CrowdStrike's premium valuation has held. The next earnings report will test the durability of that confidence.
NAB's relative strength against the ASX 200 matters more for the banking sector than a single stock call. The next valuation check is the half-year report, where bad-debt charges will test the thesis.
Phibro Animal Health's fiscal Q3 2026 slide deck is out, offering segment-level detail on Animal Health, Mineral Nutrition, and Performance Products. Investors should focus on margin trends and updated full-year guidance for the June year-end.
Philadelphia Semiconductor Index’s 11% weekly gain powered Nasdaq to record, while flat Dow revealed narrow rally. Next week will test if the rally broadens or faces a pullback.
Palladyne AI Corp. (PDYN) is pivoting to swarm AI and defense automation, a shift that carries substantial execution risk for the small-cap stock. The next contract or funding milestone will determine whether the vertical integration thesis holds.
Kelly Services published its May 8 shareholder call slide deck, giving traders a fresh look at the staffing firm's mix and competitive stance. The stock's next move depends on whether management signals an inflection in temporary employment trends.
Ave Maria Growth Fund returned -3.03% in Q1 2026, outperforming the S&P 500's -4.33% decline. The results highlight a divergence in market breadth and risk.
Sight Sciences projects $83M-$89M in 2026 revenue, banking on $6M-$8M in dry eye sales. Watch for margin sustainability and Alcon litigation updates ahead.
Nano Dimension's strategic review is reaching a critical phase. Investors must weigh the potential for a buyout against the risks of a standalone reset.
eHealth is cutting fixed costs by 20% to reach a 20% adjusted EBITDA margin by 2028. The firm is pivoting to a lifetime advisory model to stabilize cash flow.
Sensex and Nifty face renewed volatility as FIIs offload Rs 5,834.90 crore. Watch Brent crude at $102 and institutional flows for the next market catalyst.
Chime sets a $2.69B revenue target for FY2026 and launches a $200M buyback. The shift to GAAP profitability marks a new phase for the fintech's capital strategy.
Honest Company projects 4% to 6% growth for 2026, supported by a record 43.5% gross margin. Watch for margin sustainability to validate the $20M EBITDA floor.
Bruker reaffirms its 2026 outlook with $3.6B in revenue and margin expansion targets. The focus shifts to AI-driven bookings and long-term operational scaling.
SoftBank shares jumped 16.5% as Japan's Nikkei 225 hit record highs. The rally reflects a catch-up trade in AI-linked chip stocks and datacenter infrastructure.
Microfinance recovery and copper momentum define the May 7 session. Watch for HBL Engineering's potential move to ₹930 as Nifty 50 volatility persists.
AppLovin targets $1.915B to $1.945B in Q2 2026 revenue as the Axon self-serve platform launches. Monitor margin efficiency to gauge the success of the transition.
Cirrus Logic guides for $430M-$490M in Q1 revenue while signaling higher R&D spending. The shift in capital allocation creates a new test for margin stability.
Niagen Bioscience reaffirms its 10%-15% growth target for 2026, but rising marketing costs and Amazon-related headwinds create new margin pressure for NAGE.
Liberty Global shares trade at $12 despite a 20% sector rally. The valuation gap hinges on the execution of pending spin-offs and corporate restructuring plans.
Biote revenue fell 8.3% to $44.9M as a hormone pellet recall forced inventory allocations. Management maintains a $190M+ revenue target for 2026.
Mobileye's Q1 revenue beat, driven by Chinese OEMs, fails to mask the absence of new SuperVision and Chauffeur wins, keeping the stock's AI narrative in doubt.
Axon Enterprise posted 34% revenue growth in Q1, fueled by AI and drone adoption. The focus now shifts to whether software margins can recover from current levels.
Hut 8 shares climbed 35% after securing a $9.8 billion, 15-year lease for its Texas data center. The deal brings total contracted AI capacity to 597 MW.